Vizsgálati helyszín
Baptist Cancer Center
Memphis, Tennessee 38120, Egyesült ÁllamokMég nincs intézményhez kötve
- 18futó vizsgálat
- 17lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 35 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis8 vizsgálat
- 1/2. fázis4 vizsgálat
- 1. fázis3 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz10 vizsgálat
- Toboroz8 vizsgálat
- Leállították3 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC5 vizsgálat
- Amgen4 vizsgálat
- Daiichi Sankyo2 vizsgálat
- EMD Serono Research & Development Institute, Inc.2 vizsgálat
- Incyte Corporation2 vizsgálat
- és még 18
Futó vizsgálatok
Toboroz
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095· 1. fázis· Amgen· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758· 1. fázis· Amgen· Forrás
Fut, nem toboroz
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· 3. fázis· Amgen· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132· 1/2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· 3. fázis· Kite, A Gilead Company· Forrás
Fut, nem toboroz
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110· 2. fázis· Eikon Therapeutics· Forrás
Fut, nem toboroz
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114· Tempus AI· Forrás
Contact: Angela Gates
Fut, nem toboroz
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103· 2. fázis· Iovance Biotherapeutics, Inc.· Forrás
Contact: Iovance Biotherapeutics Study Team lungcelltherapy.com
Fut, nem toboroz
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
NCT04062708· 2. fázis· Alliance Foundation Trials, LLC.· Forrás
Fut, nem toboroz
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
NCT01594723· 2. fázis· Eli Lilly and Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Toboroz
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· 2. fázis· Janssen Research & Development, LLC· Forrás
Leállították
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05169437· 2. fázis· Tempus AI· Forrás
Lezárult
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· 2. fázis· Aadi Bioscience, Inc.· Forrás
Lezárult
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548· Nucleix Ltd.· Forrás
Lezárult
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591· Jazz Pharmaceuticals· Forrás
Leállították
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053· 3. fázis· Incyte Corporation· Forrás
Lezárult
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT04825834· Delfi Diagnostics Inc.· Forrás
Toboroz
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068· 1/2. fázis· Artios Pharma Ltd· Forrás
Contact: Sarah Cannon Development Innovations
Lezárult
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
NCT04155710· 1. fázis· Iovance Biotherapeutics, Inc.· Forrás
Lezárult
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
NCT03940703· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Lezárult
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
NCT03901963· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· 3. fázis· Daiichi Sankyo· Forrás
Leállították
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686· 3. fázis· ImmunityBio, Inc.· Forrás
Lezárult
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
NCT02649790· 1/2. fázis· Karyopharm Therapeutics Inc· Forrás
Lezárult
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
NCT02428712· 1/2. fázis· Fore Biotherapeutics· Forrás
Lezárult
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865· 3. fázis· Celgene· Forrás
Hibát jelzek